http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111263763-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-13 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D495-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4188 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D495-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-06 |
| filingDate | 2018-08-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-02-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2021-02-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-111263763-B |
| titleOfInvention | Crystallization of a tricyclic compound |
| abstract | The present application relates to the crystallization of a tricyclic compound, in particular to (S)‑8‑(4,4‑difluorocyclohexyl)‑8H‑thieno[3,4]pyrrolo[1,5‑a]imidazole The crystal, its preparation method, its crystal composition, pharmaceutical composition and its use. The X-ray powder diffraction spectrum of the crystal of the compound of formula I of the present application has diffraction peaks at about 11.49°, 15.05°, 20.14°, 21.53° or 21.79° with 2θ values. The crystal of the compound of formula I of the present application is relatively high in terms of physical properties, safety and metabolic stability, has good IDO inhibitory effect, and has high medicinal value. |
| priorityDate | 2017-08-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 221.